StreetAlpha.app
Home › Stocks › CRBP

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Healthcare
$3.01
▼ −10.81%
LAST CLOSE · NOV 17

Corbus is a Norwood, Massachusetts drug developer testing cancer and obesity treatments that are not yet approved. It last closed at $3.01 on Nov 17, down 10.81% on the day. The average 12-month price target from 3 analysts is $27.67 (+819.2% from the last close), with a high of $33.00 and a low of $23.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CRBP, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is CRBP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$116.3M
EPS (diluted)
−$6.04
Free cash flow
−$92.4M
Valuation
Market cap
$62.0M
20.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$30.2M
At Sep 30
Shareholder equity
$84.8M
Shares outstanding
20.6M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$45.6M−$45.6MFY2021FY2022: −$42.3M−$42.3MFY2022FY2023: −$44.6M−$44.6MFY2023FY2024: −$40.2M−$40.2MFY2024FY2025: −$78.5M−$78.5MFY2025

From CRBP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on CRBP in the past 90 days
Average 12-month target
$27.67
▲ 819.2% upside

Based on 3 analysts who set a price target on CRBP in the past 90 days. The average target is $27.67, with a high of $33.00 and a low of $23.00, compared with the last close of $3.01.

Low $23.00Avg $27.67High $33.00
Blue marker: last close $3.01
Highest target$33.00
Average target$27.67
Lowest target$23.00
Latest rating changes
MizuhoTarget lowered
Nov 12Buy$34 → $23
RBC CapitalMaintained
Nov 11Buy$33
WedbushTarget lowered
Nov 11Buy$30 → $27
OppenheimerTarget lowered
Aug 7Buy$52 → $48
HC Wainwright & Co.Target lowered
Aug 7Buy$40 → $35
DateFirmActionRatingPrice target
Nov 12MizuhoTarget loweredBuy$34 → $23
Nov 11RBC CapitalMaintainedBuy$33
Nov 11WedbushTarget loweredBuy$30 → $27
Aug 7OppenheimerTarget loweredBuy$52 → $48
Aug 7HC Wainwright & Co.Target loweredBuy$40 → $35
Loading…

Technical Analysis

CRBP · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 25% below its 20 day and 78% below its 50 day average. It is 176% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), near oversold. The nearest support is the Pivot S1 at $2.86, and the nearest resistance the Pivot at $3.10.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 15.0%/day
Key levels
$12.8852 week high+327.9%
$8.31200 day average+176.1%
$7.57100 day average+151.5%
$5.3650 day average+78.1%
$4.19Swing high (Nov 11)+39.2%
$3.7620 day average+24.9%
$3.25Pivot R1+8.0%
$3.10Pivot+3.0%
$3.01Last close
$2.86Pivot S1−5.0%
$2.8152 week low−6.6%
$2.81Swing low (Nov 5)−6.6%
Indicators
RSI (14)30.32Weak, oversold below 30Neutral
MACD-0.60Above its signal lineBullish
Stochastic29.1Middle of its rangeNeutral
ADX (14)51.9Strong downtrend
Williams %R-87.2Oversold below −80, overbought above −20Oversold
CCI (20)-123.3Oversold below −100, overbought above 100Oversold
Rate of change−22.2%Change over 10 sessionsBearish
ATR (14)$0.45Typical daily range, 15.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRBP

What happened before

See how CRBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CRBP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CRBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 15 – Sep 15
Loading…

See today’s whale options flow across the market →

CRBP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲68 buying vs 39 selling
  • ▲Held by funds +19.0 pts
  • ▲Funds holding +14
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding121107+13.1%
In funds' top 1000–
Held by funds86.0%67.0%+19.0 pts
New / increased26 / 4223 / 29+30.8%
Reduced / sold out26 / 1326 / 23−20.4%
Put/call ratio0.700.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRBP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRBP is in one of them and how their past CRBP trades turned out.

CRBP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRBP in an article yet. Here's the latest on the wider market.

About Corbus Pharmaceuticals Holdings

Corbus is a drug development company based in Norwood, Massachusetts, that is testing experimental medicines for cancer and obesity. Its cancer candidate, CRB-701, is an antibody drug conjugate designed to deliver a toxic payload to tumors that express a protein called Nectin-4. Its obesity candidate, CRB-913, is an oral pill that acts on the CB1 receptor and is designed to limit exposure in the brain. The company does not yet sell approved products, and it aims its treatments at people with solid tumors or obesity.

Headquarters
Norwood, MA